HERA-MI

Who are we

Hera-MI is a 2017 French start-up based in Nantes and founded by Sylvie Davila. Most of Hera-MI's collaborators have more than 15 years of experience in medical imaging, clinical studies and medical device certification. Breast cancer is the leading cancer in terms of frequency and mortality in women. If detected early enough, the 5-year survival rate is 99%, whereas it is only 26% for metastatic cancer. The main purpose of Hera-MI is to use AI to help early-stage breast cancer diagnosis in order to optimize patient care. Our ambition is to speed up and improve breast cancer diagnosis thanks to the development of clinical decision support solutions.